Specialties & Topics
- Arthritis/Rheumatic Disease
- Breast Cancer
- GERD/Peptic Ulcers
Join us for ongoing discussions with our physician-editors,
An ongoing dialogue on HIV/AIDS, infectious diseases,
all matters medical, and some not so medical.
New HCV Option Effective, Safe, Well-Tolerated — And Use Will Likely be Driven by Payors • December 20, 2014
As expected, the FDA approved the next treatment option for HCV on Friday — “Viekira Pak”, a (sometimes complete) regimen consisting of ritonavir-booted parataprevir and ombitasvir given as a two pills once a day, plus one pill of of dasabuvir given twice daily. It is indicated for treatment of HCV genotype 1. For those of you mechanistically inclined, […]
Notes from chief residents in family and internal medicine.
Introducing Myself • October 6, 2014
Hello! I’m excited to have an opportunity to share my adventures, experiences, and opinions from chief year with you. Transitioning between life phases can be traumatic at times, but invariably bears great potential for exponential self–growth. This year, so far, has confirmed that there is indeed much growing to be done! We held a transition event […]
An insider's notes on the practice.
Clip, Burn, Inject, or All Three? How Do You Treat Ulcer Bleeding? • October 23, 2014
As endoscopists, we have all sorts of tools to treat ulcer bleeding or other gastrointestinal bleeding, such as injection with epinephrine and thermal coaptive coagulation with heater probes or multipolar electrodes like the Gold probe. More recently, a myriad of clips have become available for use. It seems to me that both operator and ulcer […]
Audio podcasts featuring the week's news,
plus your comments and pertinent interviews.
Podcast 174: PARADIGM and heart failure • September 10, 2014
The PARADIGM-HF trial of LCZ696 — a novel compound that both blocks the renin-angiotensin system with an ARB component and blocks neprilysin’s degradation of natriuretic peptides — increased survival in heart failure by some 20% relative to enalapril. It seems to be a big deal, and the trial’s two principal authors have agreed to talk […]